144690-33-5

Basic information

• Product Name: 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester
• Synonyms: 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester;Trityl olMesartan ethyl ester;OlMesartan Ethyl Ester Trityl IMpurity;4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid ethyl ester;1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1;Ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
• CAS NO: 144690-33-5
• Molecular Formula: C₄₅H₄₄N₆O₃
• Molecular Weight: 716.86926
• Mol File: 144690-33-5.mol
• Article Data: 24

Chemical Properties

• Melting Point: 161℃
• Boiling Point: 889.7±75.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 13.18±0.29(Predicted)
• Water Solubility: 4.6μg/L at 25℃
• CAS DataBase Reference: 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester(144690-33-5)
• EPA Substance Registry System: 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester(144690-33-5)

Safety Data

• Hazardous Substances Data: 144690-33-5(Hazardous Substances Data)

Usage

Uses

Tritylolmesartan Ethyl Ester is an impurity of olmesartan medoxomil (O550000), an angiotensin II receptor antagonist and anti-hypertensive drug.

Upstream product

• 400747-06-0 C₁₆H₁₃O₂N 
• 873-32-5 2-Chlorobenzonitrile 
• 2403-54-5 2-(4-chlorophenyl)-1,3-dioxolane 
• 154709-18-9 4'-hydroxymethyl-2-(N-trityl-1H-tetrazol-5-yl)biphenyl 
• 155983-56-5 5-<2-(4'-formylbiphenylyl)>-2-(triphenylmethyl)-2H-tetrazole 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 144689-93-0 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate 
• 168265-56-3 1-benzyl-5-(4'-methyl-[1,1'-biphenyl]-2-yl)-1H-tetrazole 
• 106-38-7 para-bromotoluene 
• 76-83-5 trityl chloride 
• 144689-23-6 ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2′-(1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate 
• 38612-13-4 4-bromobenzyl benzoate 
• 28386-90-5 5-benzyl-1-phenyl-1H-tetrazole 
• 1485-70-7 N-benzylbenzamide 

Downstream Products

• 144689-23-6 ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2′-(1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate 
• 144689-63-4 olmesartan medoxomil 
• 879097-59-3 sodium 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate 
• 157356-74-6 C₄₅H₄₂N₆O₂ 
• 1114761-92-0 lithium 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(trityltetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate 
• 1337980-10-5 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate 
• 1301633-27-1 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate 
• 144690-92-6 trityl olmesartan medoxomil 
• 1301629-88-8 [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304676-48-9 (1-adamantyl)carbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304689-26-6 [1-(cyclohexylcarbonyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-90-2 (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1335030-67-5 tetradecanoyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-89-9 [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 

Relevant articles and documents

Preparation and purification method of olmesartan medoxomil key intermediate

The invention relates to a preparation and purification method of a key intermediate 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2' -(triphenylmethyl-1H-tetrazole-5-yl) (1, 1'-biphenyl)-4-yl] methyl}-1H-imidazole-5-ethyl formate (I) for preparing a chemical drug olmesartan medoxomil for treating hypertension. The invention provides a preparation and purification method for generating a compound (I) by reacting 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylic acid ethyl ester (II) with N-(triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl) tetrazole (III) in the presence of an organic solvent and an acid-binding agent. According to the preparation and purification method of the compound (I), the impurity content is effectively reduced, and the quality of a subsequent target productis improved. The method is stable in process, high in yield, good in quality, simple to operate, less in three wastes, low in production cost and suitable for industrial production, and the recoveredsolvent can be continuously used.

A olmesartan medoxomil and its preparation method (by machine translation)

The invention discloses a olmesartan medoxomil and its preparation method, the present invention discloses a olmesartan medoxomil, its chemical structure is: The present invention novel method for preparation method, comprises the following steps: (1) preparing AMST - 3 C45 H44 N6 O3 ; (2) preparing C43 H39 N6 NaO3 AMST - 4; (3) preparing C48 H44 N6 O6 AMST - 6; (4) preparing olmesartan sha tanzhi thick; (5) to make the C29 H30 N6 O6 Olmesartan medoxomil. The invention separation effect is good, relatively low viscosity system, split-phase required time is short, the time is saved but also reduces energy consumption. Filtering and separating the high recovery rate, the product quality is high, the running cost is low; process without the need to add chemical, solvent solvent, not into the secondary pollution material; equipment and automatic operation, good stability, easy to realize industrial demand. (by machine translation)

A process for the preparation of olmesartan

The invention discloses a preparation method of Olmesartan Medoxomil. The method is used for synthesizing an important intermediate 4-[2-(2-triphenylmethyl tetrazole-5-yl) phenyl] benzyl bromide (a compound III) so as to prepare the compound Olmesartan Medoxomil. The method is high in yield, easy to separate and purify, simple to operate and suitable for industrial production.